Novel methodology for producing non-natural (canonical) amino acids and rare sugars from abundant natural feedstocks. Using radical disconnections through electroorganic and photocatalytic approaches, this research enables site-selective functionalization of glycosides and amino acids, expanding accessible chemical space for pharmaceutical and biotech applications.
This research program develops innovative synthetic methods to convert abundant natural amino acids and sugars into high-value non-natural (canonical) amino acids and rare sugars. By leveraging radical disconnections through electroorganic and photocatalytic methodologies, the work unlocks new reactivity pathways that dramatically expand accessible chemical space from renewable resources. The approach addresses a critical need in pharmaceutical, nutraceutical, and specialty chemical industries where rare sugars and non-natural amino acids serve as essential building blocks but are often expensive or difficult to obtain through traditional synthesis.
Key capabilities:
Characterization and validation:
Products are isolated using chromatographic methods and fully characterized by NMR and mass spectrometry analysis, ensuring structural integrity and purity for downstream applications.
The technology is currently at an early-to-mid stage of development (TRL 3-4). Initial proof-of-concept experiments have demonstrated successful formation of ketosugars from glycosides via electroorganic methods, and beta- and gamma-amino acids from natural alpha-amino acids via photocatalytic control, achieving high yields with promising enantioselectivity. Future work will focus on expanding the substrate scope to access a broader library of selectively functionalized sugars and scaling toward larger heterocyclic amino acids through mild photocatalytic protocols.
Founded in 1614, the University of Groningen is a comprehensive public research university and among the Netherlands’ largest. Industry ties center on Zernike Campus, a research and technology park that co‑locates institutes with companies, shared labs, and pilot facilities. Clinical translation runs through University Medical Center Groningen, the integrated academic hospital, while the region’s hydrogen ecosystem links partners to major industrial sites. Research is backed by competitive national and European funding. IP & Business Development and Business Generator Groningen provide tech transfer, licensing, startup support and investor access.